Vnitr Lek 2018, 64(5):520-525 | DOI: 10.36290/vnl.2018.073

Granulocytopenia

Jaroslav Čermák1,2
1 Ústav klinické a experimentální hematologie 1. LF UK, Praha
2 Ústav hematologie a krevní transfuze, Praha

Granulocytopenia is defined as a decrease of peripheral blood granulocytes below lower limit of normal range. Patients with severe granulocytopenia - agranulocytosis exhibit < 0.5 × 109/l granulocytes in peipheral blood. Granulocytopenia may result from congenital or acquired defective production of granulocyte precursors or it may be a consequence of increased destruction of mature granulocytes, most frequently caused by immune mechanisms. Investigation of origin of granulocytopenia must be connected with exclusion of etiological agents causing secondary neutropenia (infections, autoimmune disorders, drugs, LGL syndrome). Patients with > 0.5 × 109/l of granulocytes usually do not exhibit clinical symptoms unless they do not suffer from a concomitant disease (especially immunodeficiency). Patients with severe granulocytopenia are indicated for supportive treatment and for administration of G-CSF. Children with severe congenital neutropenia (SCN) are at risk of later development of MDS or AML and are candidates for SCT when signs of disease progression appears.

Keywords: diagnosis; granulocytopenia; growth factors; pathogenesis; transplantation; treatment

Received: December 3, 2017; Accepted: March 15, 2018; Published: May 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čermák J. Granulocytopenia. Vnitr Lek. 2018;64(5):520-525. doi: 10.36290/vnl.2018.073.
Download citation

References

  1. Palmblad J, Dufour C, Papadaki H. How we diagnose neutropenia in the adult and elderly patient. Haematologica 2014; 99(7): 1130-1133. Dostupné z DOI: <http://dx.oi.org/dx.doi.org/10.3324/haematol.2014.110288>. Go to original source... Go to PubMed...
  2. Horwitz MS, Corey SJ, Grimes HL et al. ELANE mutations in cyclic and severe congenital neutropenia: genetics and pathophysiology. Hematol Oncol Clin North Am 2013; 27: 19-41. vii. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hoc.2012.10.004>. Go to original source... Go to PubMed...
  3. Zeidler C, Welte K. Kostmann syndrome and severe congenital neutropenia. Semin Hematol 2002; 39(2): 82-88. Go to original source... Go to PubMed...
  4. Smith OP. Shwachman-Diamond syndrome. Semin Hematol 2002; 39(2): 95-102. Go to original source... Go to PubMed...
  5. Freedman M, Alter BP. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias. Semin Hematol 2002; 39(2): 128-133. Go to original source... Go to PubMed...
  6. Cham B, Bonilla MA, Winkelstein J. Neutropenia associated with primary immunodeficiency syndromes. Semin Hematol 2002; 39(2): 107-112. Go to original source... Go to PubMed...
  7. Papadaki H, Eliopoulos AG, Kosteas T et al. Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood 2003; 101(7): 2591-2600. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2002-09-2898>. Go to original source... Go to PubMed...
  8. Palmblad JEW, von dem Borne AE. Idiopathic, immune, infectious, and idiosyncratic neutropenias. Semin Hematol 2002; 39(2): 113-120. Go to original source... Go to PubMed...
  9. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013; 50(3): 198-206. Dostupné z DOI: <http://dx.doi.org/10.1053/j.seminhematol.2013.06.010>. Go to original source... Go to PubMed...
  10. Gibson C, Berliner N. How we evaluate and treat neutropenia in adults. Blood 2014; 124: 1251-1258; quiz 1378. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2014-02-482612>. Go to original source... Go to PubMed...
  11. Touw IP. Game of clones: the genomic evolution of severe congenital neutropenia. Hematology Am Soc Hematol Educ Program 2015; 2015: 1-7. Dostupné z DOI: <http://dx.doi.org/10.1182/asheducation-2015.1.1>. Go to original source... Go to PubMed...
  12. Rosenberg PS, Zeidler C, Bolyard AA et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010; 150(2): 196-199. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2141.2010.08216.x>. Go to original source... Go to PubMed...
  13. Germeshausen M, Ballmaier M, Welte K. Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term study. Blood 2007; 109(1): 93-99. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2006-02-004275>. Go to original source... Go to PubMed...
  14. Skokowa J, Steinemann D, Katsman-Kuipers H et al. Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood 2014; 123(14): 2229-2237. Dostupné z DOI: <http://dx.doi.org/10.1182/blood-2013-11-538025>. Go to original source... Go to PubMed...
  15. Starkebaum G. Chronic neutropenia associated with autoimmune disease. Semin Hematol 2002; 39(2): 121-127. Go to original source... Go to PubMed...
  16. Zhang D, Loughran TP Jr. Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. Hematology Am Soc Hematol Educ Program 2012; 2012: 652-659. Dostupné z DOI: <http://dx.doi.org/10.1182/asheducation-2012.1.652>. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.